Boyer Lisa, Bernardi Christine, Leitzmann Michael, Koller Michael, Pukrop Tobias, Einhell Sabine, Heudobler Daniel, Steindorf Karen, Herr Wolfgang, Herrmann Anne
Department of Epidemiology and Preventive Medicine, Medical Sociology, University of Regensburg, Regensburg, Bavaria, Germany
Department for Internal Medicine III, University Hospital Regensburg, Regensburg, Bavaria, Germany.
BMJ Open. 2025 Jan 20;15(1):e087177. doi: 10.1136/bmjopen-2024-087177.
Tertiary prevention through physical activity and psychosocial support can positively impact patient outcomes, such as physical function and quality of life (QoL). However, more research is required on the effectiveness of strategies designed to increase the uptake of tertiary prevention programmes among cancer patients. Here, we present the protocol for a single-centre, randomised controlled pilot trial testing the preliminary effectiveness of social prescription and virtual patient information in increasing tertiary prevention among cancer patients and support persons (SPs) (ESPRIT "ffectiveness of a ocial escription and virtual patient nformation in increasing ertiary prevention" pilot trial).
Cancer patients attending medical oncology units at a university hospital in southern Germany and their SPs will be randomly allocated as a dyad to group A (social prescription (n=36)), group B (virtual patient information (n=36)) or group C (usual care (n=36)). The hospital is part of a Comprehensive Cancer Centre mainly treating patients living in rural areas. Primary outcomes are the uptake of physical activity, participation in social activities and psychosocial support. Secondary outcomes are overall QoL, knowledge of the health benefits of physical activity and psychosocial support and self-efficacy of patients. The outcomes will be assessed at baseline and after 3, 6 and 12 months of follow-up. Physical activity will be assessed using accelerometers and measured by average steps per day within the last 2 weeks after recruitment and at follow-up visits (3, 6 and 12 months). Cost-effectiveness and the time spent in the consultation, as well as potential implementation barriers and facilitators, will also be explored as part of a mixed-methods hybrid design. All data will be summarised descriptively. Regarding the analysis of primary endpoints, the average number of steps per day, as well as the summary score of the social activity log and self-report on the use of psychosocial support, will be compared between the groups (A, B and C) using analysis of variance, followed by Dunnett's test for pairwise comparisons of the intervention groups against the control group. Mean differences and 95% CIs will be presented as effect estimates. The analysis of secondary endpoints will include appropriate statistical methods such as the χ test of independence or linear regression models, which will be used to analyse secondary endpoints and to investigate factors influencing preliminary effectiveness.
This trial has been approved by the ethics committee of the University of Regensburg (reference: 23-3317-101). Signed written informed consent is required from all study participants. The results of the study will be used to inform the power calculation for future confirmatory trials and will be submitted for publication.
DRKS00033771.
通过体育活动和心理社会支持进行三级预防可对患者的预后产生积极影响,如身体功能和生活质量(QoL)。然而,对于旨在提高癌症患者对三级预防项目接受度的策略的有效性,还需要更多研究。在此,我们介绍一项单中心随机对照试验的方案,该试验旨在测试社会处方和虚拟患者信息在提高癌症患者及其支持人员(SPs)的三级预防方面的初步有效性(ESPRIT“社会处方和虚拟患者信息在提高三级预防方面的有效性”试点试验)。
在德国南部一家大学医院的肿瘤内科就诊的癌症患者及其SPs将作为二元组被随机分配到A组(社会处方(n = 36))、B组(虚拟患者信息(n = 36))或C组(常规护理(n = 36))。该医院是一个综合癌症中心的一部分,主要治疗农村地区的患者。主要结局是体育活动的参与情况、社会活动的参与情况以及心理社会支持。次要结局是总体生活质量、对体育活动和心理社会支持的健康益处的了解以及患者的自我效能感。这些结局将在基线以及随访3、6和12个月后进行评估。体育活动将使用加速度计进行评估,并通过招募后和随访就诊(3、6和12个月)时过去2周内每天的平均步数来测量。作为混合方法混合设计的一部分,还将探索成本效益、咨询所花费的时间以及潜在的实施障碍和促进因素。所有数据将进行描述性总结。关于主要终点的分析,将使用方差分析比较各组(A、B和C)每天的平均步数以及社会活动日志的汇总得分和心理社会支持使用情况的自我报告,随后使用Dunnett检验对干预组与对照组进行两两比较。平均差异和95%置信区间将作为效应估计值呈现。次要终点的分析将包括适当的统计方法,如独立性χ检验或线性回归模型,这些方法将用于分析次要终点并调查影响初步有效性的因素。
本试验已获得雷根斯堡大学伦理委员会的批准(参考号:23 - 3317 - 101)。所有研究参与者均需签署书面知情同意书。该研究的结果将用于为未来的验证性试验进行样本量计算,并将提交发表。
DRKS00033771。